Granted Patent
B2
US 9,604,961 · App. 14/650,241 · Granted Mar 28, 2017
Histone demethylase inhibitors
Inventors:
Zhe Nie (San Diego, CA); Jeffrey Alan Stafford (San Diego, CA); James Marvin Veal (Apex, NC); Michael Brennan Wallace (San Diego, CA)
Assignee:
Celgene Quanticel Research, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Claims (2)
1. A compound, or a pharmaceutically acceptable salt thereof, selected from:
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound claim 1 or a pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 8, 2016
From: QUANTICEL PHARMACEUTICALS, INC.
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 038399/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 23, 2015
From: NIE, ZHE; STAFFORD, JEFFREY ALAN; VEAL, JAMES MARVIN; WALLACE, MICHAEL BRENNAN
To: QUANTICEL PHARMACEUTICALS, INC.
Reel/Frame 036165/0626 →
Continuity (3)
Provisional Application
61734330
· Dec 6, 2012
Provisional Application
61784414
· Mar 14, 2013